MAP2K1 and Stroke: The use of MEK1 inhibition might be a way to obtain anti-stroke efficiency since it targets several transcriptional mechanisms activated by cerebral ischemia: (i) receptor upregulation causing enhanced contractility, and (ii) inflammatory gene activation, i.e., for iNOS, IL-1ß, IL-6 and TNF-α.